Tau and neurofilament light‐chain as fluid biomarkers in spinocerebellar ataxia type 3

BACKGROUND AND PURPOSE: Clinical trials in spinocerebellar ataxia type 3 (SCA3) will require biomarkers for use as outcome measures. METHODS: To evaluate total tau (t‐tau), glial fibrillary acidic protein (GFAP), ubiquitin carboxy‐terminal hydrolase L1 (UCHL1) and neurofilament light‐chain (NfL) as...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia‐Moreno, Hector, Prudencio, Mercedes, Thomas‐Black, Gilbert, Solanky, Nita, Jansen‐West, Karen R., Hanna AL‐Shaikh, Rana, Heslegrave, Amanda, Zetterberg, Henrik, Santana, Magda M., Pereira de Almeida, Luis, Vasconcelos‐Ferreira, Ana, Januário, Cristina, Infante, Jon, Faber, Jennifer, Klockgether, Thomas, Reetz, Kathrin, Raposo, Mafalda, Ferreira, Ana F., Lima, Manuela, Schöls, Ludger, Synofzik, Matthis, Hübener‐Schmid, Jeannette, Puschmann, Andreas, Gorcenco, Sorina, Wszolek, Zbigniew K., Petrucelli, Leonard, Giunti, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Neurogenetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543545/
https://www.ncbi.nlm.nih.gov/pubmed/35478426
http://dx.doi.org/10.1111/ene.15373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543545/
https://www.ncbi.nlm.nih.gov/pubmed/35478426
http://dx.doi.org/10.1111/ene.15373

Ejemplares similares